Union Hospital leads collaborative effort to advance liver cancer management in Asia-Pacific

[The content of this article has been produced by our advertising partner.]

Union Hospital recently hosted an international pre-conference event for LEAD APAC 2024, held on October 26, convening experts from across the Asia-Pacific to address the escalating challenge of hepatocellular carcinoma (HCC) in the region.  

As part of a tour to Union Hospital organised for international HCC experts, a sharing session was held to focus on the potential of advanced technologies, integrated healthcare models and public awareness campaigns in improving liver cancer outcomes. 

Key contributions came from Prof. Henry Chan Lik-yuen, Deputy Chief Hospital Manager at Union Hospital of Hong Kong, and Prof. Xie Qing of Ruijin Hospital, Shanghai. Their insights reinforced the value of cross-institutional collaboration in tackling this critical healthcare issue. 

The Asia-Pacific region carries a substantial share of the global liver cancer burden, with China alone representing nearly half of all cases worldwide.  

“Nearly half of the world’s HCC cases are found in China. The need for early detection and public awareness of liver health has never been more critical,” Prof. Xie said.  

She noted that over 80 per cent of liver cancer cases in China are diagnosed at advanced stages, significantly lowering survival rates. “Our goal is to reach 55% early diagnosis by 2030, but this requires consistent, proactive screening,” she added.